Working together to improve the detection and monitoring of resistant infections at the hospital level, taking measures to reduce infection and ensuring antibiotics' effective use.
We are delighted to announce the call for applications for the Commonwealth Partnerships for Antimicrobial Stewardship (CwPAMS) programme!
Funded by the UK Department for Health and Social Care’s Fleming Fund and managed by THET and the Commonwealth Pharmacists’ Association, CwPAMS will see up to 12 Commonwealth partnerships receive funding to tackle the growing challenge of antimicrobial resistance in Ghana, Tanzania, Uganda and Zambia.
A total of £600,000 is available to partnerships, with projects expected to run from February 2019 to April 2020.
The Fleming Fund
The Fleming Fund is a UK aid programme, helping low- and middle-income countries tackle antimicrobial resistance (AMR). Its aim is to improve the surveillance of AMR and generate relevant data that is shared nationally and globally.
Antimicrobial resistance (AMR) is a growing threat and occurs when microorganisms survive exposure to a medicine, such as antibiotics, antimalarials or antivirals, that would normally kill them. Our misuse and overuse of antibiotics are largely accelerating this global problem.
The new Commonwealth Partnerships for Antimicrobial Stewardship scheme, funded by the UK Department for Health and Social Care’s Fleming Fund, will see up to 12 Commonwealth partnerships receive funding. Multidisciplinary teams will travel to Ghana, Tanzania, Uganda and Zambia to work in partnership with local health workers to tackle the growing challenge of AMR.
A total of £600,000 is available to partnerships as part of the Fleming Fund, a wider commitment by the UK Government to spend up to £265 million of UK aid to support low and middle-income countries to enhance their surveillance of AMR by 2021.
Projects are expected to run from March 2019 to April 2020. Undertaking regular short-term visits, the partnerships will leverage the expertise of UK health institutions and technical experts to strengthen the capacity of the national health workforce and institutions to address predefined AMR challenges.
Despite great advances in modern medicine we are facing a post-antibiotic apocalypse if we do not act now.
Professor Dame Sally Davies - Chief Medical Officer, England
Antimicrobial Resistance causes
AMR poses a catastrophic threat to us all and yet until recently it has remained a neglected area of global health.
A number of factors can increase the spread of resistant microorganisms. For example, antimicrobial drugs are often used unnecessarily, which increases the risk that microorganisms can become resistant, survive and multiply. In 2016, 490,000 people developed multi-drug resistant TB, and drug resistance is starting to complicate the fight against HIV and malaria as well.
The independent Review on antimicrobial resistance estimated that,
at least 700,000 deaths each year globally are attributable to drug resistance to infections including bacterial infections, malaria and HIV/AIDS.
Unless action is taken, it is thought the burden of deaths from AMR could balloon to 10 million lives each year by 2050 and cost the global economy up to $100 trillion US Dollars.
It is estimated that 5000 deaths are already caused every year in the UK alone because antibiotics no longer work for some infections.
Rising drug resistance is a global hazard and if we do not tackle it, every day procedures such as caesarean sections, cancer therapy, and hip replacements will become extremely dangerous.
Antimicrobial resistance poses a catastrophic threat to us all and yet until recently it has remained a neglected area of global health. At THET we believe that working in partnerships is the best way to strengthen health systems both at home and overseas.
Ben Simms - Chief Executive Officer, THET
RT @HughRisebrow: However tough it is in NHS, its tougher for the 1 billion globally who never see a healthcare professional. Always inspi…